Top Markets
#1 Islamic Coin Islamic Coin +151.45%
#2 DOVU DOVU +50.49%
#3 Black Phoenix Black Phoenix +34.88%
#4 Velvet Velvet +32.10%
#5 Akedo Akedo +21.65%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +19.03%
#7 DoubleZero DoubleZero +15.69%
#8 Cross Cross +12.56%
#9 HOME HOME +12.51%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +12.12%
Coin of the day
Islamic Coin Islamic Coin
Settings
Language
ENGLISH
Currency
USD
Theme
Galera Therapeutics, Inc. Galera Therapeutics, Inc.

Galera Therapeutics, Inc.

GRTX
Rank in Stocks #33960
Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.
Share Price
$17.15
Last synced: 2026-08-03
Market Cap
$6.51M
Change (1 day)
9.80%
Change (1 year)
289.77%
Country
US
Trade Galera Therapeutics, Inc. (GRTX)

Category

Healthcare
P/B ratio for Galera Therapeutics, Inc. (GRTX)
P/B ratio as of August 2026 TTM: 1.53
According to Galera Therapeutics, Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 1.53. At the end of 2023 the company had a P/B ratio of -0.05.
P/B ratio history for Galera Therapeutics, Inc. from 2017 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
2026 (TTM) 1.53 -7,767.00%
2024 -0.02 -64.78%
2023 -0.05 -86.64%
2022 -0.37 -81.88%
2021 -2.04 -104.91%
2020 41.59 786.53%
2019 4.69 -311.62%
2018 -2.22 -99.08%
2017 -240.04 0.00%
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.2613 308.33%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.3483 314.00%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.634 136.99%
BE